Our lead product candidate, NP001, is a novel, proprietary investigational therapy that regulates activated macrophages associated with chronic neurologic diseases. NP001 transforms these activated, inflammatory macrophages that are linked to neuronal damage, back to their normal, non-inflammatory state.

Neuraltus demonstrated the ability of NP001 to significantly reduce macrophage activation and the production of inflammatory substances in laboratory models. Administration of NP001 in the most accepted animal model of ALS significantly extended survival.

Neuraltus is investigating the use of NP001 in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer’s disease (AD).